SCHEMBL8737776

SCHEMBL8737776

COc1ccc(S(N)(=O)=O)cc1Nc1nc(-c2sc(NC(C)=O)nc2C)cs1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 1/20 0.70
MAPT P10636 14/20 0.63
MEN1 O00255 13/20 0.63
KMT2A Q03164 13/20 0.63
SMN1; SMN2 Q16637 9/20 0.63
LMNA P02545 9/20 0.63
KDM4E B2RXH2 9/20 0.63
HTT P42858 7/20 0.63
HPGD P15428 7/20 0.63
GAA P10253 6/20 0.63
ALDH1A1 P00352 11/20 0.62
CFTR P13569 5/20 0.62
NR2F2 P24468 1/20 0.62
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
TDP1 Q9NUW8 1/20 0.59
ALB P02768 1/20 0.59
NPSR1 Q6W5P4 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6114666 0.99 MMP9 (0.69) MMP9MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL8738399 0.92 MMP9 (0.72) MMP9MAPTMEN1KMT2ASMN1; SMN2
Bromide SCHEMBL6114628 0.91 MMP9 (0.70) MMP9MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL8737751 0.91 MMP9 (0.57) MMP9MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL8737962 0.90 MMP9 (0.69) MMP9MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6114334 0.87 MMP9 (0.65) MMP9MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL6113962 0.87 MMP9 (0.75) MMP9MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL8737705 0.87 MEN1 (0.71) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL8738018 0.87 MEN1 (0.73) MAPTMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL6114069 0.87 MMP9 (0.78) MMP9MAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 MMP9 2/4885MAPT 3531/4885MEN1 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.